genvoya
gilead sciences ireland uc - elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide - hiv infections - antivirals for systemic use, - genvoya is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (hiv 1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.,
odefsey
gilead sciences ireland uc - emtricitabine, rilpivirine hydrochloride, tenofovir alafenamide - hiv infections - antivirals for systemic use - treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (hiv 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (nnrti) class, tenofovir or emtricitabine and with a viral load ≤ 100,000 hiv 1 rna copies/ml.,
vemlidy
gilead sciences ireland uc - tenofovir alafenamide fumarate - hepatitis b - antivirals for systemic use, - vemlidy is indicated for the treatment of chronic hepatitis b in adults and adolescents (aged 12 years and older with body weight at least 35 kg).,
symtuza
janssen-cilag international nv - darunavir, cobicistat, emtricitabine, tenofovir alafenamide - hiv infections - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza is indicated for the treatment of human immunodeficiency virus type 1 (hiv‑1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg).genotypic testing should guide the use of symtuza.
descovy 200 mg10 mg
gilead sciences israel ltd - emtricitabine; tenofovir alafenamide fumarate - film coated tablets - tenofovir alafenamide fumarate 10 mg; emtricitabine 200 mg - tenofovir disoproxil and emtricitabine - descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (hiv 1).
descovy 200 mg10 mg
gilead sciences israel ltd - emtricitabine; tenofovir alafenamide fumarate - film coated tablets - tenofovir alafenamide fumarate 10 mg; emtricitabine 200 mg - tenofovir disoproxil and emtricitabine - descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (hiv 1).בקשה לשינוי התוויה: 14/8/19addition of new info to posology section: patients undergoing haemodialysis
descovy 200 mg25 mg
gilead sciences israel ltd - emtricitabine; tenofovir alafenamide fumarate - film coated tablets - tenofovir alafenamide fumarate 25 mg; emtricitabine 200 mg - tenofovir disoproxil and emtricitabine - descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (hiv 1).
descovy 200 mg25 mg
gilead sciences israel ltd - emtricitabine; tenofovir alafenamide fumarate - film coated tablets - tenofovir alafenamide fumarate 25 mg; emtricitabine 200 mg - tenofovir disoproxil and emtricitabine - descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (hiv 1).בקשה לשינוי התוויה: 14/8/19addition of new info to posology section: patients undergoing haemodialysis
vemlidy
gilead sciences (nz) - tenofovir alafenamide fumarate 28.04mg equivalent to tenofovir alafenamide 25 mg; - film coated tablet - 25 mg - active: tenofovir alafenamide fumarate 28.04mg equivalent to tenofovir alafenamide 25 mg excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 85f120028 purified water - indicated for the treatment of chronic hepatitis b in adults.
descovy- emtricitabine and tenofovir alafenamide tablet
gilead sciences, inc. - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir alafenamide fumarate (unii: fwf6q91tzo) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine 200 mg - descovy is indicated, in combination with other antiretroviral agents, for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 35 kg. descovy is indicated, in combination with other antiretroviral agents other than protease inhibitors that require a cyp3a inhibitor, for the treatment of hiv-1 infection in pediatric patients weighing at least 14 kg and less than 35 kg. descovy is indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (prep) to reduce the risk of hiv-1 infection from sexual acquisition, excluding individuals at risk from receptive vaginal sex. individuals must have a negative hiv-1 test immediately prior to initiating descovy for hiv-1 prep [see dosage and administration (2.2) and warnings and precautions (5.2)]. limitations of use: the indication does not include use of descovy in individuals at risk of hiv-1 from receptive vaginal sex because effectiveness in this population has not been evaluated [see clinical studies